Avecho Biotechnology Ltd (ASX: AVE) Share Price and News

Dr Collier has more than 25 years fo experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialization. Dr Collier has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has taken a drug from discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals Limited from a research-based Company with a market capitalisation of $10 million to a Company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon Inc. (now subsidiary of Teva Pharmaceuticals Industries Limited) for $230 million. Prior to his commercial pharmaceutical career, Dr Collier had an academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents.

Dr Murdoch has over 30 years of experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialization of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals, based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business and President and COO of Prana Biotechnology Limited based in Australia.

Mr McNamara has over 30 years of executive and funds management experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialization advisory company and advised a number of public biotechnology / investment companies. Mr McNamara is currently Director and Chief Investment Officer of Horizon 3 Healthcare, a healthcare fund manager that has invested in Avecho Biotechnology Limited through trustee Melbourne Securities Corporation Limited.

Ms. Connell is a commercial executive with business development expertise across pharmaceutical, vaccine, medtech, consumer and digital health industries. Ms. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. For the past 20 years, Ms Connell has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specializing in business development, licensing, acquisitions and venture investment, including 12 years at Johnson & Johnson as Senior Director, New Ventures ANZ.

-

-

-

-